Article Type
Changed
Thu, 06/08/2023 - 09:08

GnRH antagonists with estrogen/progesterone are promising new uterine-sparing options for treating uterine fibroids. Two experts review data from two recent clinical trials to bring you up to speed on the benefits and risks of this treatment approach.

After reading this short article, you have an opportunity to earn 1.0 CME credits.

Click here to read more

Sponsor
This program is supported by an unrestricted educational grant provided by Myov…
Publications
Sections
Sponsor
This program is supported by an unrestricted educational grant provided by Myov…
Sponsor
This program is supported by an unrestricted educational grant provided by Myov…

GnRH antagonists with estrogen/progesterone are promising new uterine-sparing options for treating uterine fibroids. Two experts review data from two recent clinical trials to bring you up to speed on the benefits and risks of this treatment approach.

After reading this short article, you have an opportunity to earn 1.0 CME credits.

Click here to read more

GnRH antagonists with estrogen/progesterone are promising new uterine-sparing options for treating uterine fibroids. Two experts review data from two recent clinical trials to bring you up to speed on the benefits and risks of this treatment approach.

After reading this short article, you have an opportunity to earn 1.0 CME credits.

Click here to read more

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry - Sponsored CME Supplement
Gate On Date
Fri, 02/03/2023 - 13:30
Un-Gate On Date
Fri, 02/03/2023 - 13:30
Use ProPublica
CFC Schedule Remove Status
Fri, 02/03/2023 - 13:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
SF365795.2